Cocrystal Pharma Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

COCP$1.11+6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except per share data)

	December 31, 2023	December 31, 2022
Assets
Current assets:
Cash	$26,353	$37,144
Restricted cash	75	75
Tax credit receivable	890	716
Prepaid expenses and other current assets	1,773	2,243
Total current assets	29,091	40,178
Property and equipment, net	271	342
Deposits	46	46
Operating lease right-of-use assets, net (including $42 and $99 to related party)	1,851	274
Total assets	$31,259	$40,840
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses	$3,022	$976
Current maturities of finance lease liabilities	-	7
Current maturities of operating lease liabilities (including $42 and $59 to related party)	240	233
Total current liabilities	3,262	1,216
Long-term liabilities:
Operating lease liabilities (including $0 and $42 to related party)	1,613	57
Total long-term liabilities	1,613	57
Total liabilities	4,875	1,273
Commitments and contingencies	-	-
Stockholders’ equity:
Common stock $0.001 par value; 150,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 10,174 and 8,143 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	10	8
Additional paid-in capital	342,288	337,489
Accumulated deficit	(315,914)	(297,930)
Total stockholders’ equity	26,384	39,567
Total liabilities and stockholders’ equity	$31,259	$40,840

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.